Nouri Neamati

15.0k total citations · 2 hit papers
241 papers, 12.1k citations indexed

About

Nouri Neamati is a scholar working on Molecular Biology, Infectious Diseases and Virology. According to data from OpenAlex, Nouri Neamati has authored 241 papers receiving a total of 12.1k indexed citations (citations by other indexed papers that have themselves been cited), including 142 papers in Molecular Biology, 128 papers in Infectious Diseases and 97 papers in Virology. Recurrent topics in Nouri Neamati's work include HIV/AIDS drug development and treatment (125 papers), HIV Research and Treatment (97 papers) and Biochemical and Molecular Research (71 papers). Nouri Neamati is often cited by papers focused on HIV/AIDS drug development and treatment (125 papers), HIV Research and Treatment (97 papers) and Biochemical and Molecular Research (71 papers). Nouri Neamati collaborates with scholars based in United States, China and Italy. Nouri Neamati's co-authors include Yves Pommier, Bikash Debnath, Raveendra Dayam, Tino W. Sanchez, Melissa Millard, Sanjay Sunder, Armand Bankhead, Helen Ha, Abhijit Mazumder and Laith Q. Al‐Mawsawi and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.

In The Last Decade

Nouri Neamati

238 papers receiving 11.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Current Challenges and Opportunities in Treating Glioblastoma

2018 624 citations Andrea Shergalis, Armand Bankhead et al. profile →
Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases

2017 562 citations Bikash Debnath, Nouri Neamati et al. profile →

Peers

Countries citing papers authored by Nouri Neamati

Since Specialization

Citations

This map shows the geographic impact of Nouri Neamati's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nouri Neamati with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nouri Neamati more than expected).

Fields of papers citing papers by Nouri Neamati

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nouri Neamati. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nouri Neamati. The network helps show where Nouri Neamati may publish in the future.

Co-authorship network of co-authors of Nouri Neamati

This figure shows the co-authorship network connecting the top 25 collaborators of Nouri Neamati. A scholar is included among the top collaborators of Nouri Neamati based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nouri Neamati. Nouri Neamati is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	POLQ mediated end-joining promotes DNA damage tolerance in neuroblastoma 2025 ·Translational Oncology ·(unknown), (unknown), Biao Hu, Kimber Converso‐Baran, (unknown), Patrick O’Brien, Nouri Neamati, Erika A. Newman	0
2	GRP78 inhibitor YUM70 upregulates 4E-BP1 and suppresses c-MYC expression and viability of oncogenic c-MYC tumors 2024 ·Neoplasia ·Vicky Yamamoto, Dat P. Ha, Ze Liu, Miller Huang, Soma Samanta, Nouri Neamati, Amy S. Lee	5
3	Integrated transcriptomic and proteomic analysis reveals Guizhi-Fuling Wan inhibiting STAT3-EMT in ovarian cancer progression 2023 ·Biomedicine & Pharmacotherapy ·(unknown), Fangfang Chen, Ying Liu, Kang Wu, (unknown), (unknown), Nouri Neamati, (unknown)	6
4	Hyaluronic acid-bilirubin nanomedicine-based combination chemoimmunotherapy 2023 ·Nature Communications ·Yonghyun Lee, (unknown), Cheng Xu, Hannah E. Dobson, Nouri Neamati, James J. Moon	65
5	The Hydroxyquinoline Analogue YUM70 Inhibits GRP78 to Induce ER Stress–Mediated Apoptosis in Pancreatic Cancer 2021 ·Cancer Research ·Soma Samanta, Suhui Yang, Bikash Debnath, (unknown), Yuting Kuang, Kavya Ramkumar, Amy S. Lee, Mats Ljungman, Nouri Neamati	78
6	A Review of Small-Molecule Inhibitors of One-Carbon Enzymes: SHMT2 and MTHFD2 in the Spotlight 2021 ·ACS Pharmacology & Translational Science ·(unknown), (unknown), Armand Bankhead, (unknown), Nouri Neamati	35
7	Deletion of Glutathione S-Transferase Omega 1 Activates Type I Interferon Genes and Downregulates Tissue Factor 2020 ·Cancer Research ·Yibin Xu, Armand Bankhead, Xiao‐Li Tian, Jianming Tang, Mats Ljungman, Nouri Neamati	14
8	Development of 2,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of aldehyde dehydrogenase 1A (ALDH1A) as potential adjuncts to ovarian cancer chemotherapy 2020 ·European Journal of Medicinal Chemistry ·Brandt C. Huddle, Edward Grimley, (unknown), Cameron D. Buchman, (unknown), Bikash Debnath, (unknown), Shuai Mao, Siwei Li, (unknown), (unknown), Bo Wen, Duxin Sun, Nouri Neamati, Ronald J. Buckanovich, Thomas D. Hurley, Scott D. Larsen	13
9	The Dihydroorotate Dehydrogenase Inhibitor Brequinar Is Synergistic with ENT1/2 Inhibitors 2020 ·ACS Pharmacology & Translational Science ·(unknown), Hui Guo, (unknown), (unknown), (unknown), Nouri Neamati	25
10	Activation of the Unfolded Protein Response via Inhibition of Protein Disulfide Isomerase Decreases the Capacity for DNA Repair to Sensitize Glioblastoma to Radiotherapy 2019 ·Cancer Research ·Yajing Liu, Wenbin Ji, Andrea Shergalis, Jiaqi Xu, Amy M. Delaney, (unknown), Anupama Pal, Mats Ljungman, Nouri Neamati, Alnawaz Rehemtulla	49
11	Synthesis and biological evaluation of novel 2-oxo-1,2-dihydroquinoline-4-carboxamide derivatives for the treatment of esophageal squamous cell carcinoma 2018 ·European Journal of Medicinal Chemistry ·(unknown), Joyeeta Roy, (unknown), Dongyao Wang, Urarika Luesakul, Yifeng Chai, Nongnuj Muangsin, Deena S. Lasheen, Dalal A. Abou El Ella, Khaled A. M. Abouzid, Nouri Neamati	12
12	Discovery of novel 3-hydroxypicolinamides as selective inhibitors of HIV-1 integrase-LEDGF/p75 interaction 2016 ·European Journal of Medicinal Chemistry ·(unknown), Bikash Debnath, (unknown), (unknown), (unknown), Yong‐Tang Zheng, Nouri Neamati, Ya-Qiu Long	9
13	Design and synthesis of novel dihydroquinoline-3-carboxylic acids as HIV-1 integrase inhibitors 2008 ·Bioorganic & Medicinal Chemistry ·Mario Sechi, G. Rizzi, Alessia Bacchi, Mauro Carcelli, Dominga Rogolino, Nicolino Pala, Tino W. Sanchez, (unknown), Raveendra Dayam, Nouri Neamati	52
14	Synthesis and biological evaluation of novel 5(H)-phenanthridin-6-ones, 5(H)-phenanthridin-6-one diketo acid, and polycyclic aromatic diketo acid analogs as new HIV-1 integrase inhibitors 2006 ·Bioorganic & Medicinal Chemistry ·Shivaputra A. Patil, Shantaram Kamath, Tino W. Sanchez, Nouri Neamati, Raymond F. Schinazi, John K. Buolamwini	96
15	cDNA Microarray Analysis of Cytokine Expression in an Adenovirus Type 5 Infection Model of Primary Cultured Rabbit Conjunctival Epithelial Cells 2003 ·Investigative Ophthalmology & Visual Science ·(unknown), (unknown), Melvin D. Trousdale, Nouri Neamati, (unknown), Ram Kannan, (unknown)	2
16	Antiviral resistance to diketo acids is associated with the mutations T66I, L74M and S230R in the HIV-1 integrase gene 2002 ·Antiviral Research ·Myriam Witvrouw, Valery Fikkert, Bénédicte Van Maele, Christophe Pannecouque, Nouri Neamati, Terrence R. Burke, Godwin C. G. Pais, Erik De Clercq, Zeger Debyser	1
17	HIV-I integrase inhibitors: Past, present, and future 2000 ·Advances in pharmacology ·Nouri Neamati, Christophe Marchand, Yves Pommier	34
18	Inhibitors of Human Immunodeficiency Virus Integrase 1999 ·Advances in virus research ·Yves Pommier, Nouri Neamati	69
19	Synthesis of Kedarosamine, a Sugar Portion of the Chromoprotein Antibiotic Kedarcidine 1999 ·Polish Journal of Chemistry ·Waldemar Priebe, (unknown), Nouri Neamati, O. Achmatowicz, Grzegorz Grynkiewicz, Barbara Szechner	1
20	Annamycin circumvents resistance mediated by the multidrug resistance-associated protein (MRP) in breast MCF-7 and small-cell lung UMCC-1 cancer cell lines selected for resistance to etoposide 1997 ·International Journal of Cancer ·Román Pérez-Soler, Nouri Neamati, Yiyu Zou, Erasmus Schneider, L. Austin Doyle, Michael Andreeff, Waldemar Priebe, Yi‐He Ling	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact